Cohort · P2-PANC-G0633Active studySynthetic mock data
Window-of-opportunity neoadjuvant
Owner JY · last updated 2026-04-08
Size
41
Status
draft
Inclusion criteria
2
Exclusion criteria
2
Definition
Inclusion
- +Resectable PDAC by MDT consensus
- +No prior chemo or radiation
Exclusion
- −Borderline resectable disease
- −Pancreatic NET histology
draftP2-PANC-G0633Owner JYLast updated 2026-04-08
Enrollment over time
From wk 0 (n=0) to wk 20 (n=41)
Subjects in cohort (10)
| Subject | MRN | Age / Sex | Site | Enrolled | Status |
|---|---|---|---|---|---|
| PNC-WOO-001 Maria Alvarez | MRN 6027700 | 48 / F | Site 03 — Chicago | 2025-01-12 | withdrawn |
| PNC-WOO-002 Henry Müller | MRN 6027701 | 51 / M | Site 09 — Munich | 2025-01-17 | active |
| PNC-WOO-003 Rachel Sørensen | MRN 6027702 | 54 / F | Site 12 — Singapore | 2025-01-22 | active |
| PNC-WOO-004 Robert Adebayo | MRN 6027703 | 57 / M | Site 14 — Boston | 2025-01-27 | active |
| PNC-WOO-005 Priya Iversen | MRN 6027704 | 60 / F | Site 18 — Toronto | 2025-02-01 | active |
| PNC-WOO-006 Theo O'Connor | MRN 6027705 | 63 / M | Site 22 — Madrid | 2025-02-06 | active |
| PNC-WOO-007 Sara Tanaka | MRN 6027706 | 66 / F | Site 03 — Chicago | 2025-02-11 | active |
| PNC-WOO-008 Antonio Marquez | MRN 6027707 | 69 / M | Site 09 — Munich | 2025-02-16 | active |
| PNC-WOO-009 Aisha Hassan | MRN 6027708 | 72 / F | Site 12 — Singapore | 2025-02-21 | active |
| PNC-WOO-010 Omar Singh | MRN 6027709 | 75 / M | Site 14 — Boston | 2025-02-26 | active |
Linked study
P2-PANC-G0633
Neoadjuvant cytotoxic + immunomodulator window-of-opportunity
Pathologic complete response · 41/90 enrolled
Endpoints attached to this protocol
Cross-links